Please note that this program was recorded before the indication for pembrolizumab was expanded on November 13, 2020.
Pembrolizumab is now indicated in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥ 10). This approval is based on the results from KEYNOTE-355, demonstrating greater progression-free survival (PFS) in patients treated with pembrolizumab plus chemotherapy vs placebo.
The Roles of Oncology Nurses in Next-generation Approaches to the Management of Advanced HER2-Positive Breast Cancer
Andrea Rodriguez, CRNP, AOCNP
Women’s Cancer Center
Magee-Women’s Cancer Hospital
University of Pittsburgh Medical Center
Optimizing Treatment with Immune Checkpoints Inhibitors: The Collaborative Care of Patients with Triple Negative Breast Cancer
Sramila Aithal, MD
Director and Lead, Breast Center of Advanced Oncology
Medical Oncologist and Hematologist
Cancer Treatment Centers of America
This case-based online activity will cover the treatment and management of patients with HER2-positive breast cancer and triple negative breast cancer.
This activity is designed to meet the educational needs of U.S.-based nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians involved in the management of patients with breast cancer (BC). Also, this initiative is designed to meet the educational needs of U.S.-based nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians involved in the treatment of patients with triple negative breast cancer (TNBC).
LEARNING OBJECTIVES – HER-2 Positive
Upon completion of the program, attendees should be able to:
- Identify the mechanisms underlying resistance to monoclonal antibodies currently approved for first-line treatment of advanced HER2-positive breast cancer
- Discuss next-generation second-line approaches to the treatment of advanced HER2-positive breast cancer including antibody–drug conjugate technology
- Describe the mechanisms of action and clinical profiles of approved and emerging antibody–drug conjugates used to treat advanced HER2-positive breast cancer in the second-line setting
- Review the various roles for oncology nurses in the management of patients with advanced HER2-positive breast cancer who are treated or eligible for treatment with antibody–drug conjugates
LEARNING OBJECTIVES – Triple Negative Breast Cancer
Upon completion of the program, attendees should be able to:
- Explain the complementary mechanisms found with the combination of chemotherapy and immunotherapy agents in the treatment of TNBC
- Apply evidence-based data derived from clinical trials to optimize combination regimens for the treatment of patients with metastatic TNBC
- Describe patient-centered shared decision-making approaches intended to optimize oncology care in patients with TNBC
- Discuss the roles that oncology nurses can play in the management of patients with metastatic TNBC who are treated or eligible for treatment with immunotherapy
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 2.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the management of patients with BC and/or the treatment of patients with TNBC.
CNE Credits: 2.0 ANCC Contact Hours
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.0 contact hours of continuing nursing education for RNs and APNs.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
|Andrea Rodriguez, CRNP, AOCNP, has nothing to disclose.
Sramila Aithal, MD is a Speakers’ Bureau member for Pfizer, Novartis, Seattle Genetics and Puma. She was a principal investigator for pharmaceutical initiated clinical trials at CTCA.
|CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the enduring activity; and
- Complete the pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
RELEASE DATE: November 17, 2020
EXPIRATION DATE: November 17, 2021
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.